POLYMORPHISMS OF DRUG TRANSPORTERS AND CLINICAL RELEVANCE - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 654

74. Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J,
Taylor T, Clark AG, Herskowitz I, Giacomini KM. 2002. Polymorphisms in a human
kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 12:395-
405.
75. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, Tsuji A, Yokoi T. 2002. Genetic
polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-
B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J
Pharmacol Exp Ther 302:804-813.
76. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. 2005. Role of organic anion transporter
OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-
hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms.
Drug Metab Dispos 33:434-439.
77. Iwai M, Suzuki H, Ieiri I, Otsubo K, Sugiyama Y. 2004. Functional analysis of single-
nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C).
Pharmacogenetics 14:749-757.
78. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. 2005. Functional
characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and
SLCO1B1*15 + C1007G, by using transient expression systems of HeLa and HEK293
cells. Pharmacogenet Genom 15:513-522.
79. Fairchild CR, Moscow JA, O'Brien EE, Cowan KH. 1990. Multidrug resistance in
cells transfected with human genes encoding a variant P-glycoprotein and glutathione
S-transferase-pi. Mol Pharmacol 37:801-809.
80. Kimchi-Sarfaty C, Gribar JJ, Gottesman MM. 2002. Functional characterization of coding
polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol
Pharmacol 62:1-6.
81. Morita N, Yasumori T, Nakayama K. 2003. Human MDR1 polymorphism: G2677T/A and
C3435T have no effect on MDR1 transport activities. Biochem Pharmacol 65:1843-1852.
82. Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJ. 2005. MDR1 G1199A polymorphism alters
permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells.
AIDS 19:1617-1625.
83. Woodahl EL, Ho RJ. 2004. The role of MDR1 genetic polymorphisms in interindividual
variability in P-glycoprotein expression and function. Curr Drug Metab 5:11-19.
84. Letourneau IJ, Deeley RG, Cole SP. 2005. Functional characterization of nonsynonymous
single-nucleotide polymorphisms in the gene encoding human multidrug resistance pro-
tein 1 (MRP1/ABCC1). Pharmacogenet Genom 15:647-657.
85. Conrad S, Kauffmann HM, Ito K, Leslie EM, Deeley RG, Schrenk D, Cole SP. 2002.
A naturally occurring mutation in MRP1 results in a selective decrease in organic anion
transport and in increased doxorubicin resistance. Pharmacogenetics 12:321-330.
86. Haimeur A, Conseil G, Deeley RG, Cole SP. 2004. Mutations of charged amino acids in or
near the transmembrane helices of the second membrane spanning domain differentially
affect the substrate specificity and transport activity of the multidrug resistance protein
MRP1 (ABCC1). Mol Pharmacol 65:1375-1385.
87. Paulusma CC, Oude Elferink RP. 1997. The canalicular multispecific organic anion trans-
porter and conjugated hyperbilirubinemia in rat and man. J Mol Med 75:420-428.
88. Buchler M, Konig J, Brom M, Kartenbeck J, Spring H, Horie T, Keppler D. 1996. cDNA
cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp,